Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
Last trade$2.03
Day change-$1.175 (-36.72%)
Day range$2.02 – $3.03
Volume195,206
Market cap$13M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$12.96M
Price / earnings
0.07×
Price / book
-0.43×
Price / sales
2.81×
EV / sales
-8.16×
EV / EBITDA
0.75×
Profitability
Earnings per share
$45.24
Return on assets
181.24%
Return on equity
-607.72%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-0×
Current ratio
2.69×
Quick ratio
2.59×
Cash ratio
1.41×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$38.06M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for KYNB, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Revenue
-$1.47M
$3.74M
Cost of revenue
$2K
$4.11M
Gross profit
-$1.48M
-$368K
Selling, general and administrative
$9.27M
$5.86M
Research and development
$6.82M
$7.57M
Total operating expenses
$16.1M
$13.45M
Operating income
-$17.57M
-$13.82M
Interest expense
-$2.37M
-$2.43M
Income before taxes
$11.97M
-$15.13M
Income taxes
-$1K
$0
Net income
$11.97M
-$15.2M
Net income attributable to common shareholders
$11.97M
-$15.2M
EBITDA
-$17.56M
-$13.8M
Basic earnings per share
$2.96
-$3.76
Diluted earnings per share
$2.96
-$3.76
Recent news
Company coverage with links to the original publishers.
Kyntra Bio reported a quarterly loss of $3.42 per share, beating consensus estimates of $3.66 loss, representing a 6.56% earnings surprise. However, revenues of $1.76 million missed estimates by 10.38%. The stock has declined 60.8% year-to-date versus the S&P 500's 10.5% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
Adherex Technologies reported Q3 2026 earnings of $0.12 per share, beating consensus estimates of $0.09, with a 33.33% earnings surprise. Revenues reached $19.61 million, surpassing estimates by 3.69% and growing 57.4% year-over-year. The stock has gained 38.2% year-to-date, outperforming the S&P 500's 11.3% gain. However, the company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
Kyntra Bio announced the appointment of Andrew E. Singer, an experienced biotechnology finance executive with 25+ years in investment banking and corporate strategy, to its Board of Directors as an independent director and Audit Committee member effective October 1, 2026. Simultaneously, Maykin Ho stepped down after nearly eight years of service. Singer's appointment is expected to strengthen the company's financial position as it advances its rare disease and oncology pipeline.
Kyntra Bio (formerly FibroGen) will announce its fourth quarter and full year 2025 financial results on March 16, 2026, followed by a conference call with the investment community. The biopharmaceutical company is focused on developing novel therapies in oncology and rare disease, with roxadustat approved in multiple countries for anemia treatment and FG-3246 in Phase 2 development for metastatic castration-resistant prostate cancer.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.